Lung & Thoracic Cancer Trials
Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY24190
A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Determine whether any biomarker correlates with alisertib response. Determine investigator-assessed efficacy in the patient population. Determine survival outcomes in the patient population. Determine the safety profile of alisertib. Update the population pharmacokinetic (popPK) profile of alisertib
Study InformationSTUDY24689
A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
The primary objective is to compare the response rate (confirmed or unconfirmed, complete or partial) between participants with MET exon 14 skipping positive NSCLC randomized to tepotinib with or without ramucirumab. To compare the frequency of all-grade treatment- related peripheral edema as defined by CTCAE between the arms. To evaluate the frequency and severity of toxicities within each arm. To compare progression-free survival between the arms. To compare overall survival between the arms. To estimate the duration of response (DoR) among responders within each arm
Study InformationSTUDY24781
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
To evaluate whether there is an improvement in overall survival (OS) with chemotherapy combined with pembrolizumab compared to single agent pembrolizumab in this vulnerable older adult patient population.
Study InformationSTUDY25879
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The primary objective of this study is to assess the antitumor activity of amivantamab SC and Lazertinib (Cohort 1), and amivantamab SC and chemotherapy (Cohort 2) in participants with EGFRm NSCLC.
Study InformationSTUDY25963
Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer- Prospect Lung
To compare the 3-year real-world event-free survival (rwEFS) rate and overall survival (OS) between perioperative and adjuvant immunotherapy-based treatment for patients with resectable non-small cell lung cancer (dual endpoints).
Study InformationSTUDY26181
A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
To evaluate the safety of telisotuzumab vedotin at the 1.9 mg/kg, 1.6 mg/kg, and 1.6 mg/kg ->; 1.9 mg/kg dose levels, as measured by the occurrence of any-grade AEs, Grade ≥ 2 AEs, ILD (any-grade and Grade ≥ 2), peripheral neuropathy (any-grade and Grade ≥ 2), ocular surface disorders (any-grade and Grade ≥ 2), AEs leading to discontinuation, and Grade 5 AEs. To evaluate the efficacy of telisotuzumab vedotin at the 1.9 mg/kg, 1.6 mg/kg, and 1.6 mg/kg → 1.9 mg/kg dose levels, as measured by objective response (OR)
Study InformationSTUDY26313
Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Compare OS between the experimental and control arms. Compare immune DCR (iDCR), immune progression-free survival (iPFS), immune overall response rate (iORR), and immune duration of response (iDOR) as measured using immune Response Evaluation Criteria in Solid Tumors (iRECIST) between the experimental and control arms.
Study InformationSTUDY26334
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
To determine the RP2D of DB-1311 in combination with BNT327 by assessing the safety and tolerability in targeted participant populations. To determine the RP2D of DB-1311 in combination with DB-1305 by assessing the safety and tolerability in targeted participant populations.
Study InformationSTUDY26995
A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors
To determine the safety and tolerability of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. To determine the recommended dose(s) for expansion (RDE)s of NRM-823 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors. The RDE may be the maximum tolerated dose (MTD) or a biologically active dose below the MTD.
Study InformationSTUDY27379
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
The primary objective of the study is to compare overall survival (OS) between participants randomized to docetaxel and ramucirumab with or without cemiplimab (REGN2810) who have acquired resistance to platinum-based chemotherapy and immunotherapy for Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).
Study Information